- Home
- LGCY vs DBVT Comparison
LGCY vs DBVT Comparison
Compare LGCY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- DBVT
- Stock Information
- Founded
- LGCY 2009
- DBVT 2002
- Country
- LGCY United States
- DBVT France
- Employees
- LGCY N/A
- DBVT N/A
- Industry
- LGCY
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGCY
- DBVT Health Care
- Exchange
- LGCY NYSE
- DBVT Nasdaq
- Market Cap
- LGCY 87.3M
- DBVT 102.0M
- IPO Year
- LGCY 2024
- DBVT N/A
- Fundamental
- Price
- LGCY $7.17
- DBVT $9.83
- Analyst Decision
- LGCY Strong Buy
- DBVT Strong Buy
- Analyst Count
- LGCY 2
- DBVT 3
- Target Price
- LGCY $10.65
- DBVT $13.67
- AVG Volume (30 Days)
- LGCY 42.2K
- DBVT 83.0K
- Earning Date
- LGCY 05-15-2025
- DBVT 04-30-2025
- Dividend Yield
- LGCY N/A
- DBVT N/A
- EPS Growth
- LGCY 44.62
- DBVT N/A
- EPS
- LGCY 0.58
- DBVT N/A
- Revenue
- LGCY $52,722,310.00
- DBVT $3,497,000.00
- Revenue This Year
- LGCY $33.77
- DBVT $1,700.53
- Revenue Next Year
- LGCY $24.88
- DBVT $535.67
- P/E Ratio
- LGCY $12.16
- DBVT N/A
- Revenue Growth
- LGCY 32.68
- DBVT N/A
- 52 Week Low
- LGCY $3.60
- DBVT $0.44
- 52 Week High
- LGCY $10.37
- DBVT $9.90
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- DBVT 68.26
- Support Level
- LGCY N/A
- DBVT $9.18
- Resistance Level
- LGCY N/A
- DBVT $10.12
- Average True Range (ATR)
- LGCY 0.00
- DBVT 0.74
- MACD
- LGCY 0.00
- DBVT -0.01
- Stochastic Oscillator
- LGCY 0.00
- DBVT 84.32
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.